SCHEMBL9907620

SCHEMBL9907620

Cc1nc2ccc(C(=O)O)cc2c(-c2ccc(F)cc2)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 1/20 0.53
TDP1 Q9NUW8 2/20 0.51
NR4A2 P43354 1/20 0.50
KDM4E B2RXH2 4/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
HTT P42858 2/20 0.47
BCL2L1 Q07817 1/20 0.46
BAD Q92934 1/20 0.46
PTGFR P43088 2/20 0.46
DPP4 P27487 1/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 3/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
CHEK2 O96017 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
DHODH Q02127 2/20 0.44
POLB P06746 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9907607 0.87 ALDH1A1 (0.50) HTR5ATDP1NR4A2KDM4EMEN1
SCHEMBL9907617 0.85 ALDH1A1 (0.55) HTR5AKDM4EMEN1KMT2AALDH1A1
SCHEMBL9907895 0.84 HTR5A (0.76) HTR5AKDM4EMEN1KMT2AHTT
SCHEMBL9907608 0.84 HTR5A (0.72) HTR5ATDP1NR4A2KDM4EMEN1
SCHEMBL9907593 0.83 HTR5A (0.56) HTR5ATDP1KDM4EMEN1KMT2A
SCHEMBL9907644 0.81 HTR5A (0.48) HTR5ATDP1KDM4EMEN1KMT2A
SCHEMBL9907623 0.81 HTR5A (0.62) HTR5ATDP1KDM4EMEN1KMT2A
SCHEMBL9907615 0.81 HTR5A (0.59) HTR5ATDP1KDM4EMEN1KMT2A
SCHEMBL9907738 0.80 HTR5A (0.58) HTR5ATDP1KDM4EMEN1KMT2A
SCHEMBL9907450 0.80 NR4A2 (0.46) TDP1NR4A2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTR5A 1/4885TDP1 964/4885NR4A2 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.